The value of XPD and XRCC1 genotype polymorphisms to predict clinical outcome in metastatic colorectal carcinoma patients with irinotecan-based regimens

Basit Öğe Kaydı
dc.contributor.authorArtaç, Mehmet
dc.contributor.authorBozcuk, Hakan
dc.contributor.authorPehlivan, Sacide
dc.contributor.authorAkcan, Songül
dc.contributor.authorPehlivan, Mustafa
dc.contributor.authorSever, Tuğçe
dc.contributor.authorÖzdoğan, Mustafa
dc.date.accessioned2020-03-26T18:05:25Z
dc.date.available2020-03-26T18:05:25Z
dc.date.issued2010
dc.departmentSelçuk Üniversitesien_US
dc.description.abstractPrevious studies have suggested that DNA repair enzyme polymorphisms may bear prognostic value in metastatic colorectal carcinoma (MCRC). We prospectively treated 43 MCRC patients with irinotecan-based regimens (XELIRI or IFL). Allelic variants of the XRCC1 gene at codon 399 and XPD gene at codon 751 were analyzed in lymphocyte DNA by PCR-RFLP. Clinical outcome variables: overall survival (OAS), progression-free survival (PFS) and the occurrence of grade 3 or 4 hematological and gastrointestinal (GIS) toxicities were evaluated. In the univariate analysis for OAS (n = 43) only XPD and XRCC1 polymorphisms were significant (P = 0.05 and P = 0.04, respectively). After adjustment for performance status (ECOG = 0, 1 vs. 2) and disease extent (single vs. multiple metastatic site), XRCC1 genotype and performance status retained significance (HR = 2.85, P = 0.04, and HR = 3.19, P = 0.02, respectively). Gln/Gln genotype was associated with the greatest risk of death. Type of presentation (metastatic vs. local disease at first presentation) was the only significant predictor of PFS in the univariate analysis (n = 40, P = 0.003). After adjustment for performance status and disease extent, type of presentation retained its significance (HR = 4.35, P = 0.003). None of the toxicities was associated with these genotypes. XRCC1 genotype independently predicted overall survival in metastatic colorectal carcinoma patients treated with irinotecan-based chemotherapy.en_US
dc.identifier.doi10.1007/s00432-009-0720-3en_US
dc.identifier.endpage809en_US
dc.identifier.issn0171-5216en_US
dc.identifier.issue6en_US
dc.identifier.pmid19908066en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage803en_US
dc.identifier.urihttps://dx.doi.org/10.1007/s00432-009-0720-3
dc.identifier.urihttps://hdl.handle.net/20.500.12395/25421
dc.identifier.volume136en_US
dc.identifier.wosWOS:000276908200002en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSPRINGERen_US
dc.relation.ispartofJOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGYen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.selcuk20240510_oaigen_US
dc.subjectColorectal canceren_US
dc.subjectIrinotecanen_US
dc.subjectXPDen_US
dc.subjectXRCC1en_US
dc.subjectSingle nucleotide polymorphismsen_US
dc.subjectOverall survivalen_US
dc.titleThe value of XPD and XRCC1 genotype polymorphisms to predict clinical outcome in metastatic colorectal carcinoma patients with irinotecan-based regimensen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu